GSK announces cap of $35 per month on U.S. patient out-of …
GSK today announced it will cap out-of-pocket costs for eligible patients at no more than $35 per month for all of its asthma and chronic obstructive pulmonary disease (COPD) medicines,* the most prescribed portfolio of inhalers in the U.S. GSK is taking this action as part of its longstanding commitment to improving access to respiratory ...
Respiratory - GSK US
With over 50 years in respiratory care, GSK is committed to helping patients breathe better by continuously redefining treatment for COPD and asthma. We are driven by our commitment to research and uniting innovative science and technology to help people with these respiratory conditions live more comfortably.
Products | Respiratory Overview - GSKpro
A list of GSK respiratory products, for Healthcare Professionals registered in Ireland.
Trelegy Ellipta approved as the first once-daily single inhaler ... - GSK
Trelegy Ellipta is a combination of an inhaled corticosteroid (ICS), a long-acting muscarinic antagonist (LAMA), and a long-acting beta2-adrenergic agonist (LABA), delivered once-daily in GSK’s Ellipta dry powder inhaler.
Products | Respiratory - GSK US Medical Affairs
Find GSK US respiratory product information: Prescribing Information, storage and handling, and more.
FDA approves Trelegy Ellipta as the first once-daily single ... - GSK
Sep 9, 2020 · The approval means Trelegy is the first single inhaler triple therapy approved for the maintenance treatment of both asthma and COPD and is the only single inhaler triple therapy available for patients in a convenient once-daily inhalation in the US.
These Inhalers No Longer Cost More Than $35 Per Month
Mar 26, 2024 · GlaxoSmithKline (GSK) is the latest company to announce a price cap this month, following the lead of AstraZeneca and Boehringer Ingelheim, who revealed their inhaler price ceilings in March.
Discontinued Flovent inhalers replaced with generics starting Jan. 1
Jan 2, 2024 · Pharmaceutical manufacturer GlaxoSmithKline (GSK) announced that as of Jan. 1 it would no longer produce the asthma inhaler Flovent, one of the most popular preventive and maintenance...
What You Need to Know About the $35 Price Cap on Asthma Inhalers
Some major asthma inhaler manufacturers announced $35 a month caps on out-of-pocket costs. The price cap will apply to people with commercial/private insurance (through your job or federal or state marketplace) or no insurance. At some pharmacies, the savings will be automatic.
Drug Companies Step Forward with Voluntary Price Caps on Inhalers
Jun 18, 2024 · Drug companies Boehringer Ingelheim, AstraZeneca and GSK are capping out-of-pocket costs for their asthma inhalers at $35 per month for eligible patients. The price caps for Boehringer Ingelheim and AstraZeneca inhaler products went into effect on June 1, 2024.